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Plasma PCSK9 concentrations during an oral fat
load and after short term high-fat, high-fat
high-protein and high-fructose diets
Bertrand Cariou1,2,3*, Cédric Langhi1, Maëlle Le Bras1,3, Murielle Bortolotti4, Kim-Anne Lê4, Fanny Theytaz4,
Cédric Le May1, Béatrice Guyomarc’h-Delasalle1, Yassine Zaïr1,3, Roland Kreis5, Chris Boesch5, Michel Krempf1,2,3,
Luc Tappy4,6 and Philippe Costet1,3,7*
Abstract
Background: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes
hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its
expression is driven by sterol response element binding protein 2 (SREBP2) and follows a diurnal rhythm
synchronous with cholesterol synthesis. Plasma PCSK9 is associated to LDL-C and to a lesser extent plasma
triglycerides and insulin resistance. We aimed to verify the effect on plasma PCSK9 concentrations of dietary
interventions that affect these parameters.
Methods: We performed nutritional interventions in young healthy male volunteers and offspring of type 2
diabetic (OffT2D) patients that are more prone to develop insulin resistance, including: i) acute post-prandial
hyperlipidemic challenge (n=10), ii) 4 days of high-fat (HF) or high-fat/high-protein (HFHP) (n=10), iii) 7 (HFruc1,
n=16) or 6 (HFruc2, n=9) days of hypercaloric high-fructose diets. An acute oral fat load was also performed in two
patients bearing the R104C-V114A loss-of-function (LOF) PCSK9 mutation. Plasma PCSK9 concentrations were
measured by ELISA. For the HFruc1 study, intrahepatocellular (IHCL) and intramyocellular lipids were measured by
1H magnetic resonance spectroscopy. Hepatic and whole-body insulin sensitivity was assessed with a two-step
hyperinsulinemic-euglycemic clamp (0.3 and 1.0 mU.kg-1.min-1).
Findings: HF and HFHP short-term diets, as well as an acute hyperlipidemic oral load, did not significantly change
PCSK9 concentrations. In addition, post-prandial plasma triglyceride excursion was not altered in two carriers of
PCSK9 LOF mutation compared with non carriers. In contrast, hypercaloric 7-day HFruc1 diet increased plasma
PCSK9 concentrations by 28% (p=0.05) in healthy volunteers and by 34% (p=0.001) in OffT2D patients. In another
independent study, 6-day HFruc2 diet increased plasma PCSK9 levels by 93% (p<0.0001) in young healthy male
volunteers. Spearman’s correlations revealed that plasma PCSK9 concentrations upon 7-day HFruc1 diet were
positively associated with plasma triglycerides (r=0.54, p=0.01) and IHCL (r=0.56, p=0.001), and inversely correlated
with hepatic (r=0.54, p=0.014) and whole-body (r=−0.59, p=0.0065) insulin sensitivity.
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Conclusions: Plasma PCSK9 concentrations vary minimally in response to a short term high-fat diet and they are
not accompanied with changes in cholesterolemia upon high-fructose diet. Short-term high-fructose intake
increased plasma PCSK9 levels, independent on cholesterol synthesis, suggesting a regulation independent of
SREBP-2. Upon this diet, PCSK9 is associated with insulin resistance, hepatic steatosis and plasma triglycerides.
Keywords: Nutrition, Dietary intervention, PCSK9, Insulin resistance, Liver steatosis
Background
PCSK9 (Proprotein Convestase Subtilisin Kexin Type 9) is
the ninth member of the proprotein convertase (PC) fam-
ily [1]. Genetic studies have demonstrated that PCSK9 is a
major determinant of cholesterol homeostasis [2,3]. Gain-
of-function (GOF) PCSK9 mutations are associated to
autosomal dominant hypercholesterolemia and premature
atherosclerosis [4]. In contrast, loss-of-function (LOF)
PCSK9 mutations lead to low concentrations of plasma
low-density lipoprotein cholesterol (LDL-C) and confer
protection against cardiovascular disease [5]. PCSK9 is
secreted by the liver and acts as a natural inhibitor of the
LDL receptor (LDLR) pathway, by targeting the receptor
to the lysosomal pathway for degradation [3]. Current
clinical trials with monoclonal anti-PCSK9 antibodies and
SiRNA show that PCSK9 neutralisation is a promising
way to achieve low levels of LDL-C in combination with
statins [6,7].
Several studies have focussed on the metabolic determi-
nants of plasma PCSK9 concentration. Circulating PCSK9
concentrations are associated with LDL-C, plasma concen-
trations of triglycerides (TG), glucose and insulin in non-
diabetic cohorts [8-11]. The association between plasma
PCSK9 and LDL-C, although the most reproducible, is
weak as illustrated by the Dallas Heart Study where varia-
tions in fasting plasma PCSK9 only accounted for approx-
imately 7% of the variations in LDL-C [11]. At the
molecular level, PCSK9 is under the control of the sterol
regulatory element binding protein-2 (SREBP-2) [12] path-
way and as such it is downregulated by cholesterol [13].
We showed that lipogenic transcription factor SREBP-1c
can also regulate PCSK9, acting via the same response
element as SREBP-2 in the promoter of PCSK9 [14], sug-
gesting that SREBP-1c might not be dominant under non
interventional conditions. One diet that induces SREBP-1
activity is the Fructose enriched diet [15].
We previously showed that hepatic PCSK9 expression
is subjected to nutritional regulation, being decreased
upon fasting and increased following re-feeding with a
high carbohydrate diet in rodents [14]. Insulin increases
hepatic PCSK9 expression both in vitro in hepatocytes
and in vivo in mice [14]. Conversely, PCSK9 is repressed
by glucagon in rat liver [16]. Accordingly, fasting, but
not a ketogenic diet, reduces plasma PCSK9 concentra-
tions in healthy volunteers, with a ≈ 20–35% decrease
after 18 h [17,18]. However, so far there are only two
reports that describe a dietary modulation of PCSK9 in
human. The Mediterranean diet [19] and n-6 PUFAs [20]
have been shown to decrease plasma PCSK9 concentra-
tions by ≈ 12% and 13%, respectively.
Here, we assessed the variations of plasma PCSK9
concentrations following various diets that affect differ-
ently LDL-C and plasma TG. The aim was to put to test
the relationship between PCSK9 and these lipid para-
meters, as well as the hypothesis that plasma PCSK9 al-
ways reflects liver cholesterol synthesis. We used acute
fat loads, as well as several short-term dietary interven-
tions (either high-fat or high-fructose diets).
Methods
Post-prandial study
Ten healthy volunteers (5 women and 5 men; mean ±
SEM age: 25.7 ± 1.5 years) participated in the study
approved by the ethical committee of Nantes University
Hospital (Protocol referenced as n° 15/06 - BRD 06/3-E).
Patients were fasted overnight until 08.00 h, at which
time the oral fat load was given. The fat load was 180 g
of emulsified blended meal composed of 3.5% dried
skimmed milk, 19.25% butter, 23.75% peanut oil, 22%
chocolate and 30.25% water. Its energy content was 890
KCal (85% fat, 13% carbohydrates, 2% protein), with 35
g saturated fatty acid, 30 g mono-unsaturated fatty acid,
15 g poly-unsaturated fatty acid and 88 mg cholesterol
[21]. Subjects bearing the PCSK9 R104C-V114A double
mutant, acting as a dominant negative and severely
impairing PCSK9 processing and secretion, were previ-
ously described elsewhere [22] . Briefly, subject 1 is a 49
year-old man with low LDL-C (16 mg/dl) presenting
with no detectable circulating PCSK9. He has a diabetes
mellitus well-controlled with sitagliptine. Subject 2 is his
daughter, who has LDL-C values of 44 mg/dl and circu-
lating PCSK9 ~100 ng/ml. Both are heterozygous car-
riers of a double mutation affecting exon 2 of PCSK9.
Short-term dietary interventions
Post-hoc measurements of plasma PCSK9 were performed
in 2 distinct clinical trials (clinicaltrial.gov identifier
NCT00523562 and NCT01119989). Baseline characteris-
tics of the subjects, study design and diet compositions
were previously published elsewhere [23-25]. Briefly, 10
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healthy male volunteers (age: 24 ± 1 y) took part in the
protocol as previously described [23] and received either a
hypercaloric high-fat (HF) diet (51.6% saturated fat, 27.6%
monounsaturated fat, 8.8% polyunsaturated fat, 376 mg
cholesterol), a hypercaloric high-fat/high-protein (HFHP)
(52.6% saturated fat, 26.5% monounsaturated fat, 7.9%
polyunsaturated fat, 653 mg cholesterol) or an isocaloric
control diet (33.5% saturated fat, 37.0% monounsaturated
fat, 16.5% polyunsaturated fat, 226 mg cholesterol), for 4
consecutive days (NCT00523562). For the 7-day high
fructose diet (HFruc1) (16), 16 healthy male OffT2D
(mean ± SEM age: 24.7 ± 1.3 y) and 8 control subjects
(mean ± SEM age: 24 ± 1 y) participated in the study and
consumed daily, for 7 days, a control diet or an hypercalo-
ric diet enriched with 3.5 g fructose/kg fat free mass (+35%
energy intake,) (NCT00523562) [24]. For the 6-day high-
fructose diet (HFruc2) [25], 9 healthy male volunteers (age
of 23 ± 1 y; BMI: 22.6 ± 0.5 kg/m2) were initially included
in a randomized, cross-over, single-blinded study. In the
present study, dosages of lipids and PCSK9 were per-
formed in only 8 subjects due to an insufficient quantity of
serum in samples for one patient. Each participant con-
sumed a control, weight-maintenance diet with a total en-
ergy intake corresponding to 1.4 time their resting energy
requirements calculated using the Harris and Benedict
equation, and containing 55% carbohydrate, 30% lipid,
and 15% protein; and a hypercaloric (+36% energy intake)
high fructose diet supplemented with 3 g/kg/day fructose
and 3 times per day 2.2 g maltodextrin. (NCT01119989).
According to a physical examination and a brief medical
history, all participants in these 3 studies were in good
health and were not taking any medications. The studies
were performed on an out-patient basis, and subjects
received all their food as pre-packed food items with
instructions as how and when to prepare and consume
them, and where asked not to consume any other food or
drinks. Experimental periods were separated by a washout
period of at least 2 weeks (2–10 weeks). All studies were
approved by the ethical committee of Lausanne University
School of Medicine. All the participants provided written
informed consent.
Analytic procedures
Venous blood samples were obtained after an overnight
fast, between 08h00 and 09h00. For plasma PCSK9 dos-
age, blood was collected in an EDTA tube, maintained at
4°C until plasma and serum were separated and stored
at −80°C. Plasma PCSK9 concentrations were assayed in
duplicates using a commercially available quantitative sand-
wich ELISA assay and following the manufacturer instruc-
tions (Circulex CY-8079, CycLex Co, Nagano, Japan), as
previously described (14). Fasting plasma glucose was deter-
mined by the glucose oxidase method (Glucose HK, Roche
Diagnostics, Meylan, France). Serum total cholesterol, TG,
HDL cholesterol, ApoB and creatinine were measured
using routine clinical methods. LDL-C was calculated using
the Friedewald equation. Plasma lathosterol extraction and
analysis by gas chromatography–mass spectrometry was
previously described [26].
Metabolic investigation
The 2-step hyperinsulinemic euglycemic clamp and 1H
magnetic resonance spectroscopy (1H-MR spectroscopy)
used to determine insulin sensitivity, intrahepatocellular
lipid (IHCL) and intramyocellular lipid (IMCL) content,
were previously published [24]. Briefly, a 2-step hyperin-
sulinemic euglycemic clamp (0.3 and 1.0 mU.Kg-1.min-1,
90 minutes each), aimed to achieve glycaemia of 5.5
mmol/l, was performed in combination with measure of
hepatic glucose output (6,6 [2H2] glucose; hot infusion
model) [27]. Fasting hepatic insulin sensitivity index was
calculated as [100/(hepatic glucose output X insulin)]
and whole-body insulin sensitivity from the glucose dis-
posal rate at moderate and high insulinemia. IHCL and
IMCL contents were determined by 1H-MR spectros-
copy on a clinical 1.5 T MR scanner, as described previ-
ously [24]. IHCL and IMCL were expressed in units of
mmol/kg. Liver spectra were recorded from a large vol-
ume (55 cm3) during brief respiratory arrests in expir-
ation instead of by a double triggering method. Liver fat
content is expressed in units of volume percentage.
Statistical analysis
All data were expressed as means ± SEMs. The nonpara-
metric Wilcoxon’s signed-paired rank test was used to
assess the effect of each dietary intervention. All correla-
tions between plasma PCSK9 and metabolic parameters
were assessed using Spearman’s correlation test. A P-
value ≤ 0.05 was considered statistically significant. Stat-
istical analysis was performed with SAS for Windows
version 9.1 Software.
Results
Acute oral fat load does not affect plasma PCSK9
concentrations
Since we showed that PCSK9-deficient mice have reduced
post-prandial hyperlipidaemia following an oral fat load
[28], we investigated whether an acute oral fat load can
alter PCSK9 plasma concentrations in young healthy
volunteers. As expected, after the oral lipid load there was
a steep rise in plasma TG concentrations (phase 1) with a
peak at 120 min (+ 106% vs baseline) followed by a 2h
long steady state level (phase 2) and a return to normal
levels within 4 h (phase 3) (Figure 1A). Circulating PCSK9
concentrations remained unaltered (Figure 1B) during
phase 1 and phase 2, and non-significantly decreased with
fasting during phase 3 (−20 % vs baseline).
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In a step further, we verified whether two subjects
bearing the recently described PCSK9 loss of function
R104C-V114A double mutant [22] displayed an altered
postprandial lipid profile. As showed in Figure 1A,
postprandial plasma TG excursion was similar between
carriers and non carriers of PCSK9 mutation. As we
previously described [22], plasma PCSK9 concentrations
remained undetectable in subject 1 and were decreased
by ~50% in subject 2 compared to healthy volunteers. In
subject 2, circulating PCSK9 levels remained stable dur-
ing phase 1 and phase 2 and decreased by ~50% during
phase 3.
A high fructose diet raises plasma PCSK9 concentrations
We investigated the effect of various short-term diets,
including high-fat (HF), high-fat/high-protein (HFHP)
and high-fructose (HFruc) diets, on overnight fasted
plasma PCSK9 concentrations in young healthy volun-
teers. Plasma lipid profiles were previously described
[23-25] (Figure 2A-D). Briefly, HF diet was associated
with increased total-, LDL- and HDL-cholesterol (re-
spectively +9%, p = 0.069, +15%, p = 0.013, +16%, p =
0.006), decreased VLDL-triglycerides (−22%, p = 0.0017)
[23]. HFHP diet was associated with increased LDL- and
HDL-cholesterol (+20%, p = 0.007, +14%, p = 0.005) [23].
Circulating PCSK9 levels were not significantly altered
following both HF and HFHP diets, although there was
a trend toward an increase (Figure 2A).
A 7-day hypercaloric high fructose (3.5 g/kg/day) diet
(HFruc1) was performed in healthy male volunteers and
in healthy OffT2D subjects [24], who are more prone to
develop insulin resistance [29-31]. HFruc1 diet promotes
a significant rise in plasma TG levels (mean values ± SD
in control and HFruc1 diets were respectively: healthy
subjects: 57 ± 17 mg/dl and 76 ± 31 mg/dl; p=0.04;
OffT2D: 73 ± 23 and 121 ± 34 mg/dl, p<0.001) (Figure 2B-
C). HFruc1 diet did not affect LDL-C concentrations
(mean values ± SD in control and HFruc1 diets in healthy
subjects: 86 ± 8 mg/dl and 87 ± 8 mg/dl, p=ns and in
OffT2D: 111 ± 6 and 109 ± 7 mg/dl, p=ns) (Figure 2B-C).
PCSK9 levels were significantly increased following
HFruc1 diet by 27% in healthy volunteers (mean values ±
SD: 139 ± 26 vs 177 ± 48 ng/ml, p = 0.05) (Figure 2B) and
by 34% in OffT2D subjects (mean values ± SD: 172 ± 44
vs 231 ± 54 ng/ml, p = 0.001) (Figure 2C).
In another independent experiment [25], young healthy
male volunteers were subjected to a 6-day high fructose
diet (3 g/kg/day) (HFruc2). Compared to HFruc1 diet,
HFruc2 diet more severely increased plasma TG concen-
trations (72 ± 27 mg/dl vs 141 ± 58 mg/dl, p=0.01), with-
out altering LDL-C levels (mean values ± SD in CTRL
and HFruc2 diets were respectively: 92 ± 22 mg/dl and
79 ± 21 mg/dl, p=ns) (Figure 2D). In accordance with
HFruc1, fasting plasma PCSK9 concentrations were sig-
nificantly increased under fructose enriched diet by 93%
(mean values ± SD: 170 ± 23 vs 329 ± 29 ng/ml, p =
0.004) (Figure 2D).
Serum ratio to cholesterol of lathosterol is a valid indi-
cator of cholesterol synthesis in human (26). Mean lathos-
terol to cholesterol ratio was significantly increased by
113% (P=0.008) following the HF diet (Figure 3A), reflect-
ing an increase in cholesterol synthesis. It was not altered
upon HFruc1 diet in OffT2D patients (Figure 3B).
Upon high fructose diet, circulating pcsk9 concentrations
are positively associated with hepatic insulin resistance,
liver steatosis and vldl-triacylglycerols
Recent data in large cohorts have showed that plasma
PCSK9 concentrations are positively correlated with the
homeostasis model assessment-insulin resistance (HOMA-
IR) index, which is an indirect marker of insulin sensitivity
[9-11]. Here, we performed a 2-steps hyperinsulinemic-
euglycemic clamp, which is the gold standard to assess the
insulin sensitivity [32]. In healthy volunteers (n=22), with
(OffT2D: n=15) and without (n=7) a family history of type
2 diabetes mellitus, fed a control diet, there was no
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Figure 1 Oral fat load test in healthy volunteers and two
carriers of dominant negative loss-of-function double mutation
R104C/V114A. These subject were previously shown to have no or
reduced plasma PCSK9 (22). (A) Plasma TG and (B) plasma PCSK9
concentrations were determined at various time points after the oral
fat load. For the subject 1, plasma PCSK9 was undetectable all
through the test. Data represent means ± SEM.
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association between circulating PCSK9 concentrations and
both whole-body (i.e., GIR: glucose infusion rate) and hep-
atic (HGP: hepatic glucose production) insulin sensitivity
(Table 1). Moreover, PCSK9 concentrations were not cor-
related with the ectopic lipid deposition in liver (IHCL) and
skeletal muscle (IMCL), as well as with plasma lipid para-
meters (Table 1). Upon HFruc1 diet there was a significant
association between overnight-fasted plasma PCSK9 con-
centrations and both GIR and HGP under low-insulin infu-
sion dose during the clamp (Table 1 and Figure 4A-B). In
addition, circulating PCSK9 was positively correlated with
IHCL and with fasting VLDL-TG concentrations (Table 1
and Figure 4C-D). There was no statistically significant as-
sociation between PCSK9 and LDL-C or HDL-C under the
same conditions (Table 1).
Discussion
Recent studies have focused on the association between
circulating PCSK9 concentrations and metabolic para-
meters in human [8-11]. Plasma PCSK9 has been found
to be consistently associated with LDL-C, and less ro-
bustly with TG, fasting plasma glucose and HOMA-IR.
The major finding of our studies is that plasma
concentrations of PCSK9 were induced in response to
short-term HFruc diets by 27 to 93% in healthy volunteers
(Figure 2B-D). Circulating PCSK9 levels were associated
with both whole-body, hepatic insulin resistance, liver stea-
tosis and VLDL-TG (Figure 4 and Table 1). In accordance
with a regulation of PCSK9 by carbohydrate intake, we pre-
viously demonstrated that high-carbohydrate refeeding in
mice [14] increases hepatic PCSK9 mRNA and protein
levels. Our study does not explain whether changes in
plasma PCSK9 upon a high-fructose diet are causative of
the variations in VLDL-TG and what could be the molecu-
lar mechanisms involved, in particular whether PCSK9 acts
upon hepatic VLDL production. In humans, using lipopro-
tein kinetics with stable isotopes, we observed an increase
of VLDL production in 2 family members with PCSK9
GOF variant S127R [33] but it is unclear whether this is
related to this specific variant or to a general trait of
PCSK9 GOF variants. In mice, we showed that PCSK9
overexpression is accompanied with hypertriglyceridemia
due to VLDL overproduction. However this phenotype
was restricted to fasted mice, and was not observed in fed
mice [34]. Interestingly, we showed that PCSK9 is normally
decreased during fasting [14]. We hypothesized that VLDL
production was increased due to a lack of re-uptake of nas-
cent VLDL by the LDLR (as described by Twisk J. et al.
[35]). Indeed, fasting seemed to increase the effect of
PCSK9 on the LDLR degradation and these mice had vir-
tually no LDLR in their liver compared with fed mice that
overexpressed PCSK9. Fructose inhibits hepatic lipid oxi-
dation and favors VLDL-TG-synthesis [36] and it cannot
be excluded that PCSK9 was associated with nascent
VLDL particles produced by the liver. However, whether
PCSK9 is physically associated with lipoproteins remains a
controversial issue [8,37].
Plasma PCSK9 follows a diurnal rhythm that parallels
fluctuations of lathosterol to cholesterol ratio [18]. Chol-
esterol synthesis is driven by SREBP-2 that translocates
to the nucleus in response to lower cholesterol content
of the endoplasmic reticulum membrane and activates
(See figure on previous page.)
Figure 2 Effects of short-term dietary interventions. Fasting plasma PCSK9 concentrations (A-D) and LDL-C and plasma TG concentrations
(B-D) following (A) 4-day high fat (HF) or high fat/high protein (HF-HP); 7-day high fructose (HFruc1) diets in either (B) healthy volunteers or (C)
healthy offsprings of type 2 diabetic (OffT2D); (D) 6-day high fructose (HFruc2) diet in healthy volunteers. Results are expressed as means ± SEMs.
*: p<0.05, **: p<0.01; ***: p<0.001.
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Figure 3 Effects of short-term high fat (HF) and high fructose (HFRuc1) diets on markers of cholesterol synthesis. Ratios of lathosterol to
cholesterol following (A) HF diet in plasma in healthy volunteers and, (B) HFruc1 diet in OffT2D subjects. Results are expressed as means ± SEMs.
*: p<0.05, **: p<0.01; ***: p<0.001.
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HMG-Coa reductase. SREBP2 also up-regulates PCSK9
[12,39] and LDLR expression [39]. In order to estimate
how the present diets affect cholesterol synthesis, we
measured serum ratios of lathosterol to cholesterol as a
surrogate marker of cholesterol synthesis [40]. There
was an increase upon HF diets, as previously described
[41] (Figure 3A). This might relate to the non-significant
trend towards an increase of plasma PCSK9 we observed.
It is possible that the trend would turn out to be signifi-
cant with more subjects. However, upon HFruc diet, there
was no change in cholesterol synthesis (Figure 3B), but
plasma PCSK9 increased significantly, suggesting that
SREBP-2 pathway is not responsible for these changes.
We showed that SREBP-1c is able to drive the expression
of PCSK9 and that SREBP2 and SREBP1c share the same
response element on the promoter of PCSK9 [14,42]. Re-
cent studies in hamsters also support the implication of
SREBP-1c in PCSK9 regulation [43]. Diurnal fluctuations
of PCSK9 that parallel cholesterol synthesis suggest that
SREBP2 pathway is dominant over SREBP-1c activation
under non-interventional conditions. Our finding that
plasma PCSK9 is increased by a high fructose diet but that
cholesterol synthesis is not affected (Figure 3B) suggests
that PCSK9 regulation is not dependent upon SREBP-2
under this specific diet. Because SREBP-1c is induced by a
high fructose diet [15], it might be responsible for the in-
crease of plasma PCSK9.
Our study underlines the disconnection that might
take place between PCSK9 and LDL-C level under spe-
cific nutritional conditions. Indeed, the increase of LDL-
C (reported in [23]) under a HF diet was not linked to
an increase of PCSK9. Conversely, the increase of PCSK9
under HFruc diet was not associated to an increase of
LDL-C (Figure 2B-D). It is surprising that the large in-
crease of circulating PCSK9 seen under fructose (up to
93% in healthy volunteers in HFruc2) was not associated
to an increase of LDL-C (Figure 2D). Further studies are
needed to unravel the molecular mechanisms involved in
this disconnection. It is also unclear why the two studies
led to such different magnitude of increase in PCSK9
(23% for the 7 day-long vs 93% for the 6 day-long diet).
Subjects had on average similar basal concentrations of
PCSK9. It is possible that a peak of concentration occurs
at day 6 or before. However, HFruc2 induced a higher
hypertriglyceridemia than HFruc1 (+33% in HFruc1
Healthy Patients vs +107% in HFruc2 [25]), suggesting a
better efficacy of the diet.
Several elements suggested a potential association be-
tween PCSK9 and postprandial lipidaemia, in majority
represented by chylomicrons and their remnants. First
PCSK9 might influence chylomicron clearance by de-
grading the LDLR, although there is conflicting data in
Familial Hypercholesterolemia patients on the role of
the LDLR in chylomicrons clearance [44,45]. Second, we
showed that PCSK9-deficiency is associated with reduced
postprandial hyperlipidaemia in mice challenged with an
olive oil bolus, due to decreased apoB output and a modi-
fication of chylomicron size, number and catabolism [28].
Here, we failed to detect any variation in plasma PCSK9
concentrations following the acute oral fat load in healthy
Table 1 Correlations between plasma PCSK9 and metabolic parameters
correlation with PCSK9 CTRL HFruc1
Rho de Spearman p-value n Rho de Spearman p-value n
FPG (mg/dl) −0,040 0,859 22 0,266 0,232 22
GIR (1st) −0,084 0,710 22 −0,593 0,004 22
GIR (2nd) 0,045 0,844 22 −0,439 0,041 22
HGP −0,189 0,412 22 −0,019 0,934 22
HGP (1st) 0,003 0,991 22 0,542 0,009 22
HGP (2nd) −0,143 0,526 22 0,116 0,608 22
FFA (mmol/l) −0,317 0,150 22 −0,054 0,811 22
IHCL 0,182 0,417 22 0,558 0,007 22
IMCL 0,381 0,080 22 0,195 0,385 22
CT(mg/dl) 0,095 0,673 22 0,364 0,096 22
LDL-C (mg/dl) 0,178 0,427 22 0,344 0,117 22
TG (mg/dl) 0,267 0,230 22 0,538 0,010 22
VLDL-TG (mg/dl) 0,341 0,120 22 0,608 0,003 22
HDL-C (mg/dl) −0,343 0,118 22 0,006 0,980 22
Spearman’s correlations between plasma PCSK9 levels and metabolic parameters in healthy volunteers (n=7) and offsprings of type 2 diabetic patients (n=15)
after an isocaloric control (CTRL) or a high fructose (HFruc1) diet [24]. Data from both groups of patients were pooled to increase statistical power. GIR: glucose
infusion rate, HGP: hepatic glucose production, IHCL: intrahepatocellular lipid content, IMCL: intramyocellular lipid content, FPG: fasting plasma glucose, 1st
indicates the first step (0.3 mU.kg-1.min-1) and 2st the second step (1.0 mU.kg-1.min-1) of the hyperinsulinemic-euglycemic clamp.
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volunteers (Figure 1B). In addition, we found that 2 sub-
jects with PCSK9 LOF mutation responded in a similar
fashion than controls. It is possible that an olive oil load,
similar to what we did in PCSK9 knockout mice [28],
would have changed the outcome of the investigation in
these 2 subjects. However, these subjects cannot be con-
sidered as entirely deficient for PCSK9 because it is un-
clear how much wild type PCSK9 is present in the cells of
these individuals and because some wild type protein is
still being secreted for one of them. The R104CV114A
variant is not cleaved and not secreted. The variant exerts
a dominant negative effect over the wild type protein [22].
Carriers of PCSK9 R104CV114A have different concentra-
tions of plasma PCSK9 despite being both heterozygous
for the mono-allelic double mutation. For one of them
PCSK9 was virtually absent from the blood, while for the
other carrier concentrations were around 100 ng/ml. We
hypothesized that this variability is due to the dominant
effect of the variant [22]. Because the variant is not
secreted, we assume that plasma PCSK9 in these sub-
jects is the wild type protein. If plasma PCSK9 had a
role in postprandial lipemia, these two subjects would
have had a different response to the oral fat load. Of
course, some limitations to our study are to be taken
into account, as discussed below. All together, our data
suggest that plasma PCSK9 is not associated to post-
prandial hyperlipidaemia in human.
Recent studies suggest that PCSK9 may interfere with
glucose homeostasis, since: i) insulin increases PCSK9
expression in vitro in hepatocytes and in vivo in mice
and rats [14,16]; ii) the expression of PCSK9 is altered in
rodent models of diabetes [46]; and iii) circulating
PCSK9 concentrations were found to be correlated with
the level of insulin sensitivity assessed by the HOMA-R
index both in adults [11] and in children and adolescents
[9]. A recent phenotyping of PCSK9-deficient mice
A
C D
B
R=-0.59, P=0.0065 R=0.54,P=0.014
R=0.56,
P=0.001
R=0.61,
P=0.0005
-
TG
HFruc 1 diet
Figure 4 Correlations between plasma PCSK9 levels (ng/ml) and (A) glucose infusion rate (GIR) during the 1st step of
hyperinsulinemic-euglycemic clamp (mg/kg/min), (B) hepatic glucose production (HGP) during the 1st step of hyperinsulinemic-
eugyclemic clamp (mg/kg/min), (C) intrahepatocellular lipid content (IHCL)(mmol/kg), and (D) VLDL-TG (mmol/l) in healthy volunteers
(n=7) and OffT2D subjects (n=15) under a HFruc diet. Correlations were made using Spearman’s correlation test.
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revealed that they were hypoinsulinemic, hyperglycaemic
and glucose intolerant [47]. Our own investigations in
mice with a different genetic background didn’t point
out any obvious abnormality in terms of glucose homeo-
stasis and pancreatic beta cell function [48]. High fruc-
tose intake leads to hypertriglyceridemia and hepatic
insulin resistance and obesity [49]. Whether the molecule
of fructose itself is responsible for these deleterious effects
is not established because high sucrose diets leads to simi-
lar defects [49].
We show here that PCSK9 was only positively asso-
ciated with both whole-body and hepatic insulin resist-
ance in healthy volunteers (including OffT2D) when they
fed a short-term HFruc diet, but not under basal condi-
tions (Figure 4 and Table 1). Additionally, we found that
PCSK9 is associated with liver steatosis upon HFruc diet,
without any correlation with IMCL. Previous characteriza-
tions of these subjects [23,24] showed that hepatic steatosis
was not accompanied with hepatic insulin resistance when
induced by the HF, HFHP diets but that it was under the
HFruc diet. Such a positive association between circulating
PCSK9 levels and liver TG content assessed by proton
magnetic spectroscopy was previously described in the co-
hort of the Dallas Heart Study, although the level of the
correlation coefficient was weak (r = 0.13) [11]. In accord-
ance with a potential link between PCSK9 and liver steato-
sis, we recently described a positive association between
PCSK9 and gamma-glutamyl transferase levels, a marker
of hepatic steatosis, in type 2 diabetic patients [50].
Finally, our study had certain limitations. Although
our metabolic phenotyping was exhaustive, the number
of subjects is small and potentially limited the ability to
detect weak correlations. In addition, the duration of each
diet is short (≤ 7 days) and additional studies with extended
periods of dietary intervention need to be performed to
confirm our observations. The variation in the extent of
fructose-induced PCSK9 expression between the HFruc1
(+23%) and HFruc2 (+93%) diets is surprising since both
diets were similar in term of fructose and energy intake.
The only difference was the addition of maltodextrin in
HFruc2 diet. In parallel with a higher increase of PCSK9,
the hypertriglyceridemia was also more robust in HFruc2
diet. While some of our preliminary observations in a small
number of healthy volunteers (n=6) suggest that high glu-
cose diet also increase circulating PCSK9 levels (+47%,
p=0.17) (data not shown), it would be interesting to
confirm this observation in a larger number of subjects.
Although our findings suggest that plasma PCSK9 concen-
trations do not parallel cholesterol synthesis under a high
fructose diet, these studies were not designed to explore
these aspects. In particular diurnal rhythms of cholesterol
synthesis and plasma PCSK9 concentrations were not
determined in these patients. Concerning the effect of
PCSK9-deficiency on post-prandial lipid profile, we only
investigated two subjects from the same family with the
same PCSK9 LOF and that were not from the same gen-
der. It cannot be excluded that different conclusions would
emerge from a study with more subjects or with subjects
with a different LOF mutation.
In summary, we demonstrated that circulating PCSK9
levels are significantly increased following a short-term
high-fructose diet. Under these specific nutritional con-
ditions, PCSK9 concentrations were positively correlated
with insulin resistance, liver steatosis and VLDL-TG
concentrations.
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